Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$5.66 -0.08 (-1.39%)
As of 09/23/2026 03:59 PM Eastern
Compare

BCT vs. HBP, SCYB, COM, NVH, and COV

Should you buy BriaCell Therapeutics stock or one of its competitors? BriaCell Therapeutics's main competitors and comparable companies include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Covalon Technologies (COV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Helix BioPharma?

BriaCell Therapeutics (TSE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

0.0% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Helix BioPharma's return on equity of -21.54% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Helix BioPharma N/A -21.54%-279.98%

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

BriaCell Therapeutics has a beta of 2.25501, meaning that its share price is 126% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.722962, meaning that its share price is 28% less volatile than the broader market.

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Neutral

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 9 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

BriaCell Therapeutics (TSE:BCT) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Scythian Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Scythian Biosciences N/A N/A N/A

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BriaCell Therapeutics and Scythian Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

BriaCell Therapeutics (TSE:BCT) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
138267 (COM.TO) N/A N/A N/A

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
138267 (COM.TO) Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Summary

BriaCell Therapeutics and 138267 (COM.TO) tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

BriaCell Therapeutics (TSE:BCT) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

BriaCell Therapeutics has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Novoheart N/A N/A N/A

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Novoheart Neutral

Summary

BriaCell Therapeutics and Novoheart tied by winning 4 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Covalon Technologies?

BriaCell Therapeutics (TSE:BCT) and Covalon Technologies (CVE:COV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Covalon Technologies has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Covalon TechnologiesC$34.35M3.26C$2.39MC$0.1625.38

Covalon Technologies has a net margin of 12.78% compared to BriaCell Therapeutics' net margin of 0.00%. Covalon Technologies' return on equity of 15.04% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Covalon Technologies 12.78%15.04%-3.25%

BriaCell Therapeutics has a beta of 2.25501, meaning that its share price is 126% more volatile than the broader market. Comparatively, Covalon Technologies has a beta of 1.397953, meaning that its share price is 40% more volatile than the broader market.

In the previous week, Covalon Technologies had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Covalon Technologies and 0 mentions for BriaCell Therapeutics. Covalon Technologies' average media sentiment score of 1.18 beat BriaCell Therapeutics' score of 0.00 indicating that Covalon Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Covalon Technologies Positive

0.0% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Covalon Technologies shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by insiders. Comparatively, 48.7% of Covalon Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Covalon Technologies beats BriaCell Therapeutics on 11 of the 12 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$49.24MC$3.98BC$7.31BC$12.84B
Dividend Yield13.70%3.63%2.52%6.27%
P/E Ratio-6.7413.88274.0940.36
Price / SalesN/A1,353.16642.559.35
Price / CashN/A113.2977.8082.29
Price / Book1.7515.4010.474.69
Net Income-C$2.37M-C$22.82MC$3.49BC$299.09M
7 Day Performance-4.39%-1.74%-0.68%0.01%
1 Month Performance17.43%-6.20%-3.18%-2.14%
1 Year Performance-60.56%30.64%15.12%20.17%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$5.66
-1.4%		N/A-56.6%C$49.24MN/AN/A16
HBP
Helix BioPharma
N/AC$1.40
+1.4%		N/A-31.3%C$106.93MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel